Zhao Lue Ping, Papadopoulos George K, Skyler Jay S, Kwok William W, Bondinas George P, Moustakas Antonis K, Wang Ruihan, Pyo Chul-Woo, Nelson Wyatt C, Geraghty Daniel E, Lernmark Åke
Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
School of Public Health, University of Washington, Seattle, Washington, USA.
JCI Insight. 2025 Mar 4;10(7):e184348. doi: 10.1172/jci.insight.184348.
HLA-DR genes are associated with the progression from stage 1 and stage 2 to onset of stage 3 type 1 diabetes (T1D), after accounting HLA-DQ genes with which they are in high linkage disequilibrium. Based on an integrated cohort of participants from 2 completed clinical trials, this investigation finds that, sharing a haplotype with the DRB103:01 (DR3) allele, DRB301:01:02 and *02:02:01 have respectively negative and positive associations with the progression. Furthermore, we uncovered 2 residues (β11, β26, participating in pockets 6 and 4, respectively) on the DRB3 molecule responsible for the progression among DR3 carriers; motif RY and LF respectively delay and promote the progression (hazard ratio [HR] = 0.73 and 2.38, P = 0.039 and 0.017, respectively). Two anchoring pockets 6 and 4 probably bind differential autoantigenic epitopes. We further investigated the progression association with the motifs RY and LF among carriers of DR3 and found that carriers of the motif LF have significantly faster progression than carriers of RY (HR = 1.48, P = 0.019 in unadjusted analysis; HR = 1.39, P = 0.047 in adjusted analysis), results of which provide an impetus to examine the possible role of specific DRB3-binding peptides in the progression to T1D.
在考虑了与HLA - DR基因处于高度连锁不平衡状态的HLA - DQ基因后,发现HLA - DR基因与1型糖尿病(T1D)从1期和2期进展到3期发病相关。基于来自2项已完成临床试验参与者的综合队列,本研究发现,与DRB103:01(DR3)等位基因共享单倍型时,DRB301:01:02和*02:02:01分别与疾病进展呈负相关和正相关。此外,我们在DRB3分子上发现了2个分别参与6号和4号口袋的残基(β11和β26),它们负责DR3携带者中的疾病进展;基序RY和LF分别延缓和促进疾病进展(风险比[HR]分别为0.73和2.38,P分别为0.039和0.017)。6号和4号两个锚定口袋可能结合不同的自身抗原表位。我们进一步研究了DR3携带者中基序RY和LF与疾病进展的关联,发现基序LF的携带者比RY的携带者疾病进展明显更快(未调整分析中HR = 1.48,P = 0.019;调整分析中HR = 1.39,P = 0.047),这些结果为研究特定DRB3结合肽在T1D进展中的可能作用提供了动力。